Myriad Genetics, Inc. MYGN was a big mover last session, as its shares rose over 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for …
Jan 12 The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the …
Myriad Genetics Inc. MYGN reported adjusted earnings per share (EPS ... It has a four-quarter average earnings surprise of 8.45%. Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the …